Ocular Therapeutix Price To Sales vs. Current Valuation
| OCUL Stock | USD 10.06 0.31 3.18% |
Ocular Therapeutix Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.61 | 0.9096 |
|
|
For Ocular Therapeutix profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ocular Therapeutix to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ocular Therapeutix utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ocular Therapeutix's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ocular Therapeutix over time as well as its relative position and ranking within its peers.
Ocular |
Ocular Therapeutix's Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ocular Therapeutix Current Valuation vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ocular Therapeutix's current stock value. Our valuation model uses many indicators to compare Ocular Therapeutix value to that of its competitors to determine the firm's financial worth. Ocular Therapeutix is regarded fifth in price to sales category among its peers. It is rated top company in current valuation category among its peers reporting about 47,495,686 of Current Valuation per Price To Sales. At this time, Ocular Therapeutix's Price To Sales Ratio is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ocular Therapeutix by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Ocular Current Valuation vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Ocular Therapeutix |
| = | 25.89 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Ocular Therapeutix |
| = | 1.23 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Ocular Current Valuation vs Competition
Ocular Therapeutix is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 2.9 Billion. Ocular Therapeutix totals roughly 1.23 Billion in current valuation claiming about 42% of equities under Health Care industry.
Ocular Therapeutix Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ocular Therapeutix, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ocular Therapeutix will eventually generate negative long term returns. The profitability progress is the general direction of Ocular Therapeutix's change in net profit over the period of time. It can combine multiple indicators of Ocular Therapeutix, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -9 M | -8.6 M | |
| Operating Income | -82.4 M | -86.5 M | |
| Income Before Tax | -80.7 M | -84.8 M | |
| Total Other Income Expense Net | 1.6 M | 1.7 M | |
| Net Loss | -80.7 M | -84.8 M | |
| Income Tax Expense | 2.8 M | 3 M | |
| Net Loss | -67.1 M | -70.4 M | |
| Non Operating Income Net Other | 16.8 M | 17.7 M | |
| Net Loss | -63.9 M | -67.1 M | |
| Interest Income | 2.9 M | 3.1 M | |
| Net Interest Income | -6.1 M | -6.4 M | |
| Change To Netincome | 2.8 M | 2.7 M | |
| Net Loss | (1.01) | (1.06) | |
| Income Quality | 0.87 | 1.25 | |
| Net Income Per E B T | 0.80 | 0.89 |
Ocular Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ocular Therapeutix. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ocular Therapeutix position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ocular Therapeutix's important profitability drivers and their relationship over time.
Use Ocular Therapeutix in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ocular Therapeutix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocular Therapeutix will appreciate offsetting losses from the drop in the long position's value.Ocular Therapeutix Pair Trading
Ocular Therapeutix Pair Trading Analysis
The ability to find closely correlated positions to Ocular Therapeutix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ocular Therapeutix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ocular Therapeutix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ocular Therapeutix to buy it.
The correlation of Ocular Therapeutix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ocular Therapeutix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ocular Therapeutix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ocular Therapeutix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ocular Therapeutix position
In addition to having Ocular Therapeutix in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Fabricated Products Thematic Idea Now
Fabricated Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
To fully project Ocular Therapeutix's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ocular Therapeutix at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ocular Therapeutix's income statement, its balance sheet, and the statement of cash flows.